BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, May 10, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 2, 2015
View Archived Issues
University of California, Oakland and WARF patent bacterial DNA gyrase inhibitors
Read More
First patient dosed in phase II trial of tipifarnib in patients with HRAS-mutant urothelial cancer
Read More
HTIT licenses marketing rights to Oramed's oral insulin in China
Read More
Combination of PI3K/Akt and JAK/PIM inhibitors shows synergistic antitumor effect
Read More
First patient dosed in phase II study of N-91115 for cystic fibrosis
Read More
FDA clears IND application for SB-FIX
Read More
Repros Therapeutics receives FDA complete response letter for enclomiphene
Read More
Amcure awarded research grant from German Ministry of Education
Read More
Adding DNA-damaging properties to PARP inhibitor enhances potency
Read More
Marathon Pharmaceuticals launches expanded access program for deflazacort in DMD
Read More
Active Biotech patents S100A9 inhibitors
Read More
Celon Pharma announces PDE10A inhibitors
Read More
Medshine Discovery and North China Pharmaceutical report FXa inhibitors
Read More
Actelion Pharmaceuticals introduces antibacterial compounds
Read More
University of Illinois patents amphotericin B epimer
Read More
NINDS grant supports Hillhurst's development of HBI-002 for acute cerebral injury
Read More
Novo Nordisk licenses antibodies targeting insulin receptor from XOMA
Read More
Mylan outlines plans for antiretroviral treatment TLE-400
Read More
BioCellChallenge reports in vivo findings confirming efficacy of ImmunoCellin technology
Read More
First-in-class FGFR inhibitor demonstrates FGFR subtype selectivity
Read More
Maximal virologic suppression reported at 1 year in phase IIb extension study of PRO-140
Read More
MabVax files IND application for anticancer antibody
Read More
Topline data from phase III TELECAST study of telotristat etiprate in carcinoid syndrome
Read More
BMS and National Comprehensive Cancer Network collaborate to study PD-L1 expression
Read More
MPP and University of Liverpool collaborate to develop nanoformulated antiretrovirals
Read More